Results 1 to 10 of about 1,348,486 (207)

Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients

Arthritis Research & Therapy, 2018
BackgroundThe aim of this study was to assess the outcomes of remission induction in patients with IgG4-related disease (IgG4-RD) in our cohort, and to investigate the characteristics, prognosis, and risk factors in the patients failed of remission ...
Liwen Wang, Panpan Zhang, Mu Wang, R. Feng, Y. Lai, Linyi Peng, Y. Fei, Xuan Zhang, Yan Zhao, Xiaofeng Zeng, Fengchun Zhang, Wen Zhang   +11 more
semanticscholar   +3 more sources

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial [PDF]

Annals of the Rheumatic Diseases, 2019
Objectives Cyclophosphamide induction regimens are effective for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but are associated with infections, malignancies and infertility.
R. Jones, T. Hiemstra, J. Ballarin, D. Blockmans, P. Brogan, A. Bruchfeld, M. Cid, K. Dahlsveen, J. D. de Zoysa, G. Espígol-Frigolé, P. Lanyon, C. Peh, V. Tesar, A. Vaglio, M. Walsh, D. Walsh, G. Walters, L. Harper, D. Jayne   +18 more
semanticscholar   +2 more sources

Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2021
Importance The current standard induction therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis is the combination of high-dose glucocorticoids and cyclophosphamide or rituximab.
S. Furuta, D. Nakagomi, Yoshihisa Kobayashi, M. Hiraguri, T. Sugiyama, K. Amano, T. Umibe, H. Kono, K. Kurasawa, Y. Kita, R. Matsumura, Y. Kaneko, K. Ninagawa, K. Hiromura, S. Kagami, Y. Inaba, H. Hanaoka, K. Ikeda, H. Nakajima   +18 more
semanticscholar   +1 more source

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study

Arthritis Research & Therapy, 2021
Objectives To investigate the safety and effectiveness of mepolizumab (MPZ), an anti-interleukin-5 antibody, as remission induction therapy for severe eosinophilic granulomatosis with polyangiitis (EGPA).
M. Ueno, I. Miyagawa, T. Aritomi, K. Kimura, S. Iwata, K. Hanami, S. Fukuyo, S. Kubo, Y. Miyazaki, S. Nakayamada, Yoshiya Tanaka   +10 more
semanticscholar   +1 more source

A real-world assessment of mycophenolate mofetil for remission induction in eosinophilic granulomatosis with polyangiitis

Rheumatology International, 2021
Eosinophilic granulomatosis with polyangiitis (EGPA) is a form of ANCA-associated vasculitis (AAV). Clinical trials demonstrating the efficacy of mycophenolate mofetil (MMF) for remission induction in AAV excluded patients with EGPA. Despite this, MMF is
Mariana Philobos, A. Perkins, M. Karabayas, P. Dospinescu, N. Fluck, D. Kidder, Fiona A. Chapman, N. Dhaun, N. Basu   +8 more
semanticscholar   +1 more source

Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.

Journal of Clinical Oncology, 2019
PURPOSE To identify effective and less toxic therapy for children with acute myeloid leukemia, we introduced clofarabine into the first course of remission induction to reduce exposure to daunorubicin and etoposide.
J. Rubnitz, Norman J. Lacayo, H. Inaba, K. Heym, R. Ribeiro, J. Taub, Jennifer L. McNeer, B. Degar, D. Schiff, A. Yeoh, E. Coustan-Smith, Lei Wang, B. Triplett, S. Raimondi, J. Klco, J. Choi, S. Pounds, C. Pui   +17 more
semanticscholar   +1 more source

Expression Pattern of Long Non-coding RNA Growth Arrest-specific 5 in the Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia

Journal of Medical Biochemistry, 2019
Summary Background Long non-coding RNA growth arrest-specific 5 (GAS5) is deregulated in many cancers because of its role in cell growth arrest and apoptosis.
V. Gasic, B. Stanković, B. Zukic, D. Janić, L. Dokmanovic, N. Krstovski, J. Lazic, Goran Milosevic, M. Lucafò, G. Stocco, G. Decorti, S. Pavlovic, N. Kotur   +12 more
semanticscholar   +1 more source

Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings

Journal of Market Access & Health Policy, 2019
Background: Corticosteroids may be temporarily effective for ulcerative colitis (UC), but long-term use increases the risk of adverse drug reactions.
M. Okayasu, H. Ogata, Y. Yoshiyama
semanticscholar   +1 more source

Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia

Open Access Macedonian Journal of Medical Sciences, 2019
BACKGROUND: Detection of minimal residual disease (MRD) in the early phase of therapy is the most powerful predictor of relapse risk in children with acute lymphoblastic leukaemia (ALL).
A. Jovanovska, K. Martinova, S. Kocheva, Z. Trajkova-Antevska, B. Coneska-Jovanova, I. Panovska-Stavridis, S. Stankovikj, S. Trajkova, A. Dimovski   +8 more
semanticscholar   +1 more source

Effectiveness of Remission Induction Strategies for Early Rheumatoid Arthritis: a Systematic Literature Review

Current Rheumatology Reports, 2019
Purpose of ReviewTo review the effectiveness of remission induction strategies compared to single csDMARD-initiating strategies according to current guidelines in early RA.Recent FindingsTwenty-nine studies, heterogeneous on, e.g., specific treatment ...
M. Verhoeven, P. Welsing, J. Bijlsma, J. V. van Laar, F. Lafeber, J. Tekstra, J. Jacobs   +6 more
semanticscholar   +1 more source